by Manisha Kashyap, PhD
Diagnosing many of the genetic disorders is often a journey through complex and unfamiliar territory. For many patients and their families who will be affected by these diseases, identification of the genetic cause of their disease represents more than the practical medical benefit, as it is important emotionally as well. However, in approximately 60% of the cases with neurodevelopmental disorders (NDDs), this search for a genetic explanation remains fruitless. Two back-to-back studies, published in Nature Medicine (May 31, 2024) (D. Greene et al.) (University of Cambridge and Icahn School of Medicine) and in Nature (July 11, 2024) (Y. Chen et al.) (University of Oxford) by independent research teams using independent techniques and involving individuals with a wide array of NDDs, have pinpointed an important genetic factor hitherto unknown: variation in the RNU4-2 gene. The research teams behind the studies determined that changes in RNU4-2, a gene implicated in RNA splicing, were linked to a wide array of NDDs, thus refining further the range of genetic underpinnings associated with these conditions.
The open-access Nature Medicine article is titled “Mutations in the U4 snRNA Gene RNU4-2 Cause One of the Most Prevalent Monogenic Neurodevelopmental Disorders.” The open-access Nature article is titled “De Novo Variants in the RNU4-2 snRNA Cause a Frequent Neurodevelopmental Syndrome.”
The significance of these two papers is indicated by the extensive highlights coverage in Nature (“Rare Developmental Disorder Caused by Variants in a Small RNA Gene”), Nature Genetics (“RNU4-2 Variants Cause Neurodevelopmental Disorders”), and Nature Reviews Neuroscience (“Variants in a Noncoding Gene Drive Prevalent Neurodevelopmental Disorder”).
Discovering the Hidden Role of RNU4-2
Traditionally, genetics research has been focused mainly on protein-coding genes, which are just 1.5% of the human genome. The remaining 98.5%—the so-called “dark matter” of the genome—has so far been largely neglected, especially for diagnostic purposes in a clinical setting. One of the genes in this gigantic noncoding region is RNU4-2, encoding a small nuclear RNA species known as snRNA, playing a core role in messenger RNA splicing. It plays a critical role in the processing of genetic information with very high accuracy, but had not previously been implicated in human disease.
In their landmark studies, the research teams, led respectively by Greene and Chen, used the in-depth data generated by the 100,000 Genomes Project. This project includes full genomic sequences from thousands of patients with rare diseases, many of whom have conditions that have gone genetically unsolved.
By examining these previously neglected regions of the genome, researchers were able to find RNU4-2 variants in a surprisingly large proportion of cases—115 cases, Chen et al. report, and 73 cases, according to Greene et al.—making it among the most common genes associated with developmental disorders discovered so far.
The Genetics of RNU4-2 and the Clinical Impact
The variants discovered in RNU4-2 are particularly noteworthy because they occur in a non-coding gene—a class of genes that do not produce proteins but are involved in other crucial cellular mechanisms. The results give more value to RNU4-2 for conditions of clinical relevance due to their genetic trait.
The most common variant proximally identified with the RNU4-2 sequence is n.64_65 insT which is a single nucleotide insertion recognized as inheritance from the mother in most cases. This variant was not found in the unaffected parents, and it also largely seemed to be absent in general population databases; thus further highlighting its possible pathogenic relevance.
Clinically, individuals with RNU4-2 variants share a distinctive set of symptoms. In such patients, intellectual disability, microcephaly (small head size), short stature, seizures, and brain abnormalities are evident. The presence of common facial features among affected individuals further suggests a specific genetic syndrome associated with RNU4-2 variants. The identification of this genetic signature offers clinicians and healthcare professionals a new diagnostic tool, which could expedite the diagnosis for other patients with similar symptoms who have yet to receive a genetic explanation for their condition.
Broader Implications for Genetic Research and Diagnostics
Identification of RNU4-2 as a significant contributor to NDDs has profound and far-reaching ramifications for research and clinical practice.
First, and most significantly, it rebuts the history of focusing on the protein-coding portions of the genome within the domain of genetic diagnostics. Exome sequencing, or the sequencing of protein-coding regions, has traditionally been the method used to uncover genetic bases of disease. However, these examples showcase the ability of whole-genome sequencing (WGS) to uncover causative non-coding variants that exome sequencing alone would miss.
Given the results of these studies and considering the fact that WGS is an expensive and technically challenging procedure, such supplementary costs will be justified in a subject with an undiagnosed case after exome sequencing. It will probably mean that WGS will turn into an increasingly important tool for the diagnosis of a rare disease as genomic technologies keep developing and becoming more affordable. Moreover, these findings could stimulate a realignment of the focus of this research, promoting a more thorough study of the non-coding regions of the genome, which may hopefully yield even more important variants that have the potential to cause disease.
Research Validation and Future Directions
The reliability of the results regarding RNU4-2 is well-supported through rigorous validation across multiple cohorts. After the initial discovery, the research teams replicated their findings in additional datasets, confirming the association between RNU4-2 variants and NDDs. Moreover, the studies demonstrated that these variants are likely responsible for 0.4–0.5% of all NDDs.
Future Directions
In the future, studies are likely to focus on the understanding and the identification of the precise molecular mechanisms through which the variants of RNU4-2 that cause diseases exert their effects. Because RNU4-2 has a function in RNA splicing, a crucial process required for the accurate gene expression, mutations or disruptions to this gene may have far-reaching consequences on cellular function. Further research may help to uncover these pathways and, in the long run, make it more possible to develop specific targeted therapies and treatments against RNU4-2-associated diseases in affected individuals.
Conclusion
In summary, these studies represent an important advance in the field of genetic medicine by identifying RNU4-2 variants as a common cause of NDDs. For so many affected individuals and families who have gone through a very long and frustrating diagnostic odyssey, these findings are answers—and hope—for the future. With the increased understanding of the non-coding regions of the genome, the opportunities for new findings that may potentially change patient care are looking more and more promising. The work and studies by Chen et al. and Greene et al. illustrate the power of comprehensive genomic analysis and exploration, as well as serving as a reminder that our biology’s secrets very often lie in the places least expected.
Nature Medicine Abstract
The Nature Medicine abstract reads as follows: “Most people with intellectual disability (ID) do not receive a molecular diagnosis following genetic testing. To identify new etiologies of ID, we performed a genetic association analysis comparing the burden of rare variants in 41,132 noncoding genes between 5,529 unrelated cases and 46,401 unrelated controls. RNU4-2, which encodes U4 small nuclear RNA, a critical component of the spliceosome, was the most strongly associated gene. We implicated de novo variants among 47 cases in two regions of RNU4-2 in the etiology of a syndrome characterized by ID, microcephaly, short stature, hypotonia, seizures, and motor delay. We replicated this finding in three collections, bringing the number of unrelated cases to 73. Analysis of national genomic diagnostic data showed RNU4-2 to be a more common etiological gene for neurodevelopmental abnormality than any previously reported autosomal gene. Our findings add to the growing evidence of spliceosome dysfunction in the etiologies of neurological disorders.”
Nature Abstract
The Nature abstract reads as follows: “Around 60% of individuals with neurodevelopmental disorders (NDDs) remain undiagnosed after comprehensive genetic testing, primarily of protein-coding genes. Large genome-sequenced cohorts are improving our ability to discover new diagnoses in the non-coding genome. Here we identify the non-coding RNA RNU4-2 as a syndromic NDD gene. RNU4-2 encodes the U4 small nuclear RNA (snRNA), which is a critical component of the U4/U6.U5 tri-snRNP complex of the major spliceosome. We identify an 18 base pair region of RNU4-2 mapping to two structural elements in the U4/U6 snRNA duplex (the T-loop and stem III) that is severely depleted of variation in the general population, but in which we identify heterozygous variants in 115 individuals with NDDs. Most individuals (77.4%) have the same highly recurrent single base insertion (n.64_65insT). In 54 individuals in whom it could be determined, the de novo variants were all on the maternal allele. We demonstrate that RNU4-2 is highly expressed in the developing human brain, in contrast to RNU4-1 and other U4 homologues. Using RNA sequencing, we show how 5′ splice-site use is systematically disrupted in individuals with RNU4-2 variants, consistent with the known role of this region during spliceosome activation. Finally, we estimate that variants in this 18-base-pair region explain 0.4% of individuals with NDDs. This work underscores the importance of non-coding genes in rare disorders and will provide a diagnosis to thousands of individuals with NDDs worldwide.”
[Nature Medicine article] [Nature article] [Nature Genetics Highlights article] [Nature Reviews Neursoscience highlights article] [Nature News & Views article]
About the Writer
Dr. Manisha Kashyap (Dr. MK)
BDS (Hons), MSc, PhD (Healthcare)
Manisha Kashyap earned a BS in Dentistry (Gold Medalist) and an MS in Clinical Research, and she is a driven PhD scholar in Health Policy and Management.
With a rich background as a Drug Safety Analyst for top-tier bio pharmaceutical companies, she blends clinical expertise with a passion for advancing healthcare accessibility and innovation through her writing career for the love of science and technology via MedKnow Research Writing Solutions.
Dr. Kashyap’s PhD thesis is on “Artificial Intelligence (AI) and Public Health: Harnessing the Power of AI for Enhanced Public Health Policy and Management.”